IDEAYA Biosciences, Inc. IDYA
We are a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. 10-K, Item 1
- Headquarters
- South San Francisco, CA
- CEO
- Yujiro S. Hata
- Next results
- around Feb 16, 2027
What changed
13 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 17, 2026 against Feb 18, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
9 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 8 checks found nothing to note
-
Critical audit matters changedNew this year: Collaboration Revenue Recognition - Certain Servier Performance Obligation (“As described in Notes 10 and 11 to the financial statements, in August 2025, the Company entered into an exclusive license agreement with Les Laboratoires Servier (Servier) pursuant to which the Company granted to Servier an exclusive license under certain intellectual property rights controlled by ”). No longer listed: Accrued Research and Development Expenses Related to Contract Research Organizations
-
Cash from operations −$71.1M vs net income −$113.7M (FY ending Dec 31, 2025)
7 more checks with nothing to note
-
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
13 paragraphs in Risk Factors that were not in the 10-K filed Feb 18, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
To date, we have primarily financed our operations through the sale of equity securities and payments received under our collaboration and licensing agreements. We will be required to seek additional funding in the future and currently intend to
-
Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
We will need to successfully initiate and complete our own Phase 1 clinical trials and later-stage and pivotal clinical trials in order to obtain FDA or a comparable foreign regulatory body’s approval to market our product candidates. Carrying out clinical trials and the submission of regulatory filings is a complicated process. As an…
-
Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
As another example, the regulatory landscape related to clinical trials in the EU recently evolved. The EU CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the EU Clinical Trials Directive required a separate CTA to be submitted in each member state in which…
-
Item 1A · new paragraph · not in the 10-K filed Feb 18, 2025 10-K, ITEM 1A
Aside from PARP inhibitors, such as Lynparza, Rubraca, Zejula and Talzenna, no synthetic lethality small molecule inhibitor therapeutics have been approved to date by the FDA or other comparable regulators. AEs in future clinical trials of our product candidates or in clinical trials of others developing similar products and the…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $50.9M | $23.4M | $7.0M | $218.7M |
| Net income | −$58.7M | −$113.0M | −$274.5M | −$113.7M |
| Operating cash flow | −$87.2M | −$115.2M | −$247.6M | −$71.1M |
| Free cash flow | −$90.6M | −$117.6M | −$251.4M | −$73.5M |
Revenue, FY2019 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$218.7M ▲ 3024.4% in FY2025−$113.7M in FY2025−$73.5M in FY2025
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 3, 2026Yujiro S. Hata (Chairman and Chief Executive Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 330,316 shares, runs to Jul 2, 2027
-
8-KNov 3, 2026Quarterly results 8-K item 2.02
-
10-QNov 3, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
IDEAYA Biosciences, Inc., South San Francisco, CA · from the 10-K filed Feb 17, 2026
We are a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications.
- Headquarters
- South San Francisco, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 3, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 17, 2026 (open at SEC), compared with the 10-K filed Feb 18, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IDYA/export.csv") into a cell.